Supernus Pharmaceuticals Long Term Debt 2011-2024 | SUPN

Supernus Pharmaceuticals long term debt from 2011 to 2024. Long term debt can be defined as the sum of all long term debt fields.
Supernus Pharmaceuticals Annual Long Term Debt
(Millions of US $)
2023 $
2022 $
2021 $379
2020 $362
2019 $345
2018 $329
2017 $
2016 $4
2015 $7
2014 $26
2013 $34
2012 $11
2011 $23
2010 $
Supernus Pharmaceuticals Quarterly Long Term Debt
(Millions of US $)
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31 $400
2021-12-31 $379
2021-09-30 $375
2021-06-30 $370
2021-03-31 $366
2020-12-31 $362
2020-09-30 $377
2020-06-30 $372
2020-03-31 $349
2019-12-31 $345
2019-09-30 $341
2019-06-30 $337
2019-03-31 $333
2018-12-31 $329
2018-09-30 $326
2018-06-30 $322
2018-03-31 $318
2017-12-31
2017-09-30
2017-06-30 $1
2017-03-31 $3
2016-12-31 $4
2016-09-30 $6
2016-06-30 $6
2016-03-31 $6
2015-12-31 $7
2015-09-30 $8
2015-06-30 $9
2015-03-31 $11
2014-12-31 $26
2014-09-30 $26
2014-06-30 $29
2014-03-31 $28
2013-12-31 $34
2013-09-30 $60
2013-06-30 $59
2013-03-31 $8
2012-12-31 $11
2012-09-30 $14
2012-06-30 $17
2012-03-31 $20
2011-12-31 $23
2011-09-30
2011-06-30
2011-03-31
2010-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $1.872B $0.608B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00